Michael Arenberg
Chief Operating Officer chez IMAGO BIOSCIENCES, INC.
Profil
Michael H.
Arenberg was the founder of IntraEAR, Inc. founded in 1996, where he held the title of VP-Sales, Marketing & Business Development from 1996 to 1999.
Currently, he is the Chief Operating & Business Officer at Imago BioSciences, Inc. since 2022.
Previously, he worked at DURECT Corp.
from 1999 to 2022, where he held the title of Senior VP-Corporate & Business Development from 2012 to 2018.
Mr. Arenberg has a graduate degree from the University of Denver and an MBA from Leavey School of Business.
Postes actifs de Michael Arenberg
| Sociétés | Poste | Début |
|---|---|---|
| IMAGO BIOSCIENCES, INC. | Chief Operating Officer | 23/03/2022 |
Anciens postes connus de Michael Arenberg
| Sociétés | Poste | Fin |
|---|---|---|
| DURECT CORPORATION | Director of Finance/CFO | 17/03/2022 |
IntraEAR, Inc.
 IntraEAR, Inc. Medical SpecialtiesHealth Technology Part of DURECT Corp., IntraEAR, Inc. is a private company that develops drug delivery devices for inner-ear maladies. The company is based in Greenwood Village, CO. IntraEAR was acquired by DURECT Corp. on October 06, 1999. The company was founded by Dan K. Arenberg, Michael H. Arenberg. | Founder | 01/01/1999 |
Formation de Michael Arenberg
| University of Denver | Graduate Degree |
| Leavey School of Business | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| DURECT CORPORATION | Health Technology |
| Entreprise privées | 2 |
|---|---|
IntraEAR, Inc.
IntraEAR, Inc. Medical SpecialtiesHealth Technology Part of DURECT Corp., IntraEAR, Inc. is a private company that develops drug delivery devices for inner-ear maladies. The company is based in Greenwood Village, CO. IntraEAR was acquired by DURECT Corp. on October 06, 1999. The company was founded by Dan K. Arenberg, Michael H. Arenberg. | Health Technology |
Imago BioSciences, Inc.
 Imago BioSciences, Inc. BiotechnologyHealth Technology Imago BioSciences, Inc. operates as a clinical-stage biopharmaceutical company that develops novel anti-cancer therapeutics. It translates science of genetics and epigenetics enzymes into novel medicines for treating myeloid diseases that pose challenges to patients, families, and physicians. The company also translates insights into transformative therapies that alter the history of disease allowing patients to live longer and disease-free lives. Imago BioSciences was founded by Hugh Young Rienhoff, Jr., Laura G. Eichorn and Jennifer Peppe on March 29, 2012 and is headquartered in Redwood City, CA. | Health Technology |
